🇺🇸 tocilizumab IV in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 9

Most-reported reactions

1. Respiratory Failure — 2 reports (22.22%)
2. Acidosis — 1 report (11.11%)
3. Blood Creatinine Increased — 1 report (11.11%)
4. Bradycardia — 1 report (11.11%)
5. Hypernatraemia — 1 report (11.11%)
6. Hypertriglyceridaemia — 1 report (11.11%)
7. Leukocytosis — 1 report (11.11%)
8. Renal Impairment — 1 report (11.11%)

Source database →

Frequently asked questions

Is tocilizumab IV approved in United States?

tocilizumab IV does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for tocilizumab IV in United States?

Hoffmann-La Roche is the originator. The local marketing authorisation holder may differ — check the official source linked above.